The potassium-chloride co-transporter 3 (KCC3) is mutated in hereditary motor and sensory neuropathy with agenesis of the corpus callosum (HMSN/ACC); however, the molecular mechanisms of HMSN/ACC pathogenesis and the exact role of KCC3 in the development of the nervous system remain poorly understood. The functional regulation of this transporter by protein partners is also largely unknown. Using a yeast two-hybrid approach, we discovered that the C-terminal domain (CTD) of KCC3, which is lost in most HMSN/ACC-causing mutations, directly interacts with brain-specific creatine kinase (CK-B), an ATPgenerating enzyme that is also a partner of KCC2. The interaction of KCC3 with CK-B was further confirmed by in vitro glutathione S-transferase pull-down assay, followed by sequencing of the pulled-down complexes. In transfected cultured cells, immunofluorescence labeling showed that CK-B co-localizes with wild-type KCC3, whereas the kinase fails to interact with the inactive truncated KCC3. Finally, CK-B's inhibition by DNFB results in reduction of activity of KCC3 in functional assays using Xenopus laevis oocytes. This physical and functional association between the co-transporter and CK-B is, therefore, the first protein -protein interaction identified to be potentially involved in the pathophysiology of HMSN/ACC.
INTRODUCTION
Hereditary motor and sensory neuropathy with agenesis of the corpus callosum (HMSN/ACC) is an autosomal recessive severely invalidating and ultimately fatal disease. Both development and maintenance of the integrity of the nervous system are impaired, and the most striking histopathological findings include abnormal axonal migration through the brain midline and massive swelling of peripheral nerves accompanied by demyelination (1) . HMSN/ACC is a monogenic disease caused by mutations in the KCC3 gene, which codes for the potassium-chloride co-transporter 3 (KCC3) (2) . Since KCC3 allows the outward transport of K þ and Cl 2 ions and subsequently water through the plasma membrane, the protein is thought to be involved in regulatory volume decrease (RVD) response and ion homeostasis (3, 4) . Therefore, we suspect that a complete loss of function of the transporter may account for the swollen axons observed in patients, a hallmark of HMSN/ACC pathology. However, many aspects of the disease remain to be explained.
Several topology studies reported that KCC3 is a large integral glycoprotein that contains 12 membrane-spanning domains and includes a variable N-terminal region and a large C-terminal domain (CTD) within the cytoplasm (3,5 -7) . Truncation of the CTD is predicted to occur in most of the HMSN/ACC mutations (8/9 mutations) (2, 8, 9) , suggesting a key role for this part of the protein. We have so far performed functional studies of the two mutations most commonly found worldwide (2436delG, T813fsX813 and 3031C!T, R1011X), and demonstrated that: (i) a mutation in exon 18, which is found in the French-Canadian population at a high rate, truncates a third of the whole protein and inactivates the co-transporter (2); (ii) a mutation in exon 22 produces the R1011X truncated form of KCC3 in ethnically diverse populations, and also inactivates the transporter, even if only a third of the CTD is missing (9) . These data reinforce the hypothesis that the CTD in KCC3 is critical for function, possibly due to defective proteinprotein interactions.
In a recent study, it was shown that the neuronal-specific KCC2, a protein involved in the determination of resting (Cl 2 )i, interacts with brain-type creatine kinase (CK-B) via the CTD of this co-transporter (10) . Using an electrophysiological approach, the authors demonstrated that CK-B activates KCC2 in their HEK293 cellular transfection model (11) . It was also strongly suggested that creatine kinases play a key role in the activation of potassium-chloride co-transport in red blood cells (12) . The key requirement for creatine kinases in mammalian cells, including CK-B, is primarily linked to the cytoplasmic instability of ATP: in order to shuffle energy within the cell, the inorganic phosphate (Pi) of ATP is conjugated with creatine to produce phosphocreatine. Phospho-creatine is high in energy and stable, but, contrary to ATP, its energy is unavailable for direct usage. In the nervous system, phospho-creatine is the prime substrate for CK-B, which catalyses the transfer of Pi from phosphocreatine to ADP. CK-B thus allows the production of ATP in a precisely controlled spatial and temporal manner (13) .
The aims of the present study are to (i) investigate the potential interaction between CK-B and KCC3, (ii) assess the impact of this key protein -protein interaction on the function of the transporter and (iii) deduct its contribution to HMSN/ACC pathogenesis. Our findings show that KCC3 naturally occurring truncation mutations lead to a loss of interaction between the transporter and CK-B. This interaction has a major impact on the activity of the co-transporter, similar to the functional defect of HMSN/ACC truncated KCC3.
RESULTS

Yeast two-hybrid and GST pull-down assays identify CK-B as a binding partner of KCC3
The CTDs of KCC2 and KCC3 are highly homologous, excepting KCC2's extra domain that confers its K þ /Cl 2 constitutive transport activity (14, 15) . The average amino acid sequence identity is even higher within the distal portion of the CTD (see the partial alignment of the last 140 amino acids of potassium-chloride co-transporters in Fig. 1 ), where the interaction between KCC2 and CK-B has been reported to occur (10) . To verify if a specific interaction of KCC3 with CK-B could be detected, we undertook a yeast-two hybrid (Y2H) approach by using a chimerical KCC3 CTD (amino acids 669-1150) construct as the bait. A positive interaction in yeast cells co-transformed with KCC3 and CK-B constructs was identified when cells were grown on selective medium lacking leucine, tryptophan and histidine ( -L/W/H) ( Fig. 2A) . The growth was restricted on this selective medium, compared with the growth on -L/W medium or positive controls grown on -L/W/H medium (data not shown). A weak but discernable b-galactosidase activity was detected by colony lift assay (Fig. 2B) . Our results support the hypothesis of an interaction between KCC3 and CK-B in this Y2H system; however, this interaction appears to be restricted, either due to a weak binding between the two proteins or due to properties inherent to the Y2H assay method.
To confirm the interaction between CK-B and KCC3 detected by Y2H assay, we subsequently performed an in vitro binding assay using the glutathione S-transferase (GST) fusion protein affinity binding method, which allows the highly sensitive identification of binding partners by subsequent protein sequencing. For the GST pull-down assay, we fused the whole CTD of KCC3 in frame with a GST epitope and expressed the chimeric fusion protein in the presence of 1 mM IPTG (Fig. 3A) . Since CK-B is strongly expressed in the nervous system, as detected in Figure 3B and reported by others (16) , immobilized GST-tagged KCC3 CTD proteins were incubated with a total protein extract from mouse brain. The resulting protein complexes (Fig. 3C) were identified by LC-MSMS analysis, which showed that GST-CTD co-precipitates with the endogenously expressed CK-B (Fig. 3D) . These results strongly support the specificity of the interaction between KCC3 and CK-B.
Wild-type KCC3 co-localizes with CK-B in vivo and in vitro (Fig. 3B ) are both endogenously expressed in the mouse brain at important levels; therefore, using dual-fluorescence immunohistochemical assays, we ascertained the cellular co-expression of endogenous KCC3 and CK-B in adult mouse brain. We found that co-localization of the two proteins was especially strong in cells of the hippocampus and the corpus callosum (Fig. 4A) .
To further characterize the interaction between these two proteins, we transfected HeLa cells with a construct bearing the full-length KCC3 cDNA. Adequate expression of transfected KCC3 and endogenous CK-B was confirmed by Western blot (Fig. 4B and C) . Using immunofluorescence labeling, we determined that, as expected, overexpressed KCC3 exhibited a membranous localization, with occasional intracellular localization. The interest of using HeLa cells in this study lies on the fact that they not only have a relatively low endogenous KCC3 expression, as detected by Western blot (Fig. 4B) and by immunofluorescence labeling of non-transfected cells (Fig. 4D ), but these commonly used cells also express CK-B endogenously. Using dual-immunofluorescence labeling for KCC3 and CK-B, we observed that overexpressed KCC3 and endogenous CK-B co-localize in HeLa cells: the fluorescence patterns of CK-B and KCC3 substantially overlapped at the cell periphery (Fig. 4D) .
The KCC3 region of interaction with CK-B lies in the distal 140 amino acids of the co-transporter's CTD Since the CTD is the region that mediates KCC3's binding to CK-B, we next attempted to determine the impact on this interaction of the least deleterious of the HMSN/ACC-associated KCC3 CTD truncation mutations. Most of the inherited nonsense mutations so far identified in the KCC3 gene lie upstream of the CTD and result in the total loss of the CTD.
2704
Human Molecular Genetics, 2008, Vol. 17, No. 17
However, we have recently characterized a less deleterious truncation, R1011X, which results in the loss of less than a third of the CTD (the most distal 140 amino acids of KCC3), which leads to the loss of function of the co-transporter (9). Therefore we tested the ability of the smallest KCC3 amino acid fragment whose loss is known to cause HMSN/ACC to interact with CK-B in Y2H system. For this purpose, the whole CTD of human KCC3 (amino acids 669-1150; CTD in the Figure) and the last 140 amino acids (140-CTD) were used as 'bait' proteins, while human CK-B was used as 'prey'. We found a positive interaction between both CTD fragments and CK-B (Fig. 5A ). This result implies that the specific site of interaction between KCC3 and CK-B lies within the last 140 amino acids of KCC3's CTD, suggesting that all HMSN/ACC truncation mutations identified so far necessarily lead to the loss of the interaction with CK-B. We further tested the capacity of smaller distal fragments of KCC3 to interact with CK-B by Y2H, and determined the precise localization of the CK-B binding site to be within the last 18 amino acids of KCC3's CTD ( Fig. 5B and Supplementary Material, Figure S ).
Loss of co-localization of truncated KCC3 and CK-B implies an impaired interaction between the two proteins
The ability of CK-B to bind KCC3's CTD and the fact that the loss of the CTD (or segments of it) leads to HMSN/ACC, suggest that the disruption of this interaction could play a crucial role in disease pathogenesis. To further investigate the impact of the HMSN/ACC-associated C-terminal R1011X mutation on KCC3's interaction with CK-B, we used dual-immunofluorescence labeling of HeLa cells transfected with the mutant form of KCC3 (R1011X) lacking the last 140 amino acids. In contrast to what was observed for wild-type KCC3, we observed that truncated KCC3 is almost completely retained in the cytoplasm of transfected HeLa cells (Fig. 5D) . Furthermore, the co-localization of the co-transporter and CK-B seen for wild-type KCC3 is lost in the R1011X mutant (Fig. 5D ). This finding confirms that the HMSN/ACC-associated truncation abrogates the interaction of the mutant co-transporter with its natural partner, CK-B.
Inhibition of CK-B blocks KCC3's activity in a Xenopus laevis oocyte flux assay
To ascertain the nature of the interaction between KCC3 and CK-B at a functional level, a flux assay was developed that monitored ion transport triggered by KCC3's activation upon hypotonic stimulation. For this, wild-type KCC3 was expressed in Xenopus laevis oocytes ( Fig. 6A ) and the flux of 86 Rb þ across the plasma membrane was measured as a marker of KCC3 activity; the specificity of the transport was confirmed in parallel by using 1 mM furosemide (from 2618+325 to 832+99 pmol/oocyte/45 min; ANOVA P , 0.0005), an efficient cation-chloride co-transporter inhibitor. In order to evaluate the impact of creatine kinase on KCC3 activity, KCC3-injected oocytes were subsequently incubated with 50 mM of 2,4-Di-Nitro Fluoro Benzene (DNFB), which was reported as a 'fairly good' creatine kinase inhibitor (11, 12) . In these conditions, the 86 Rb þ flux was shown to be inhibited to the same extent as that observed under furosemide inhibition (977+48 pmol/oocyte/45 min; ANOVA P , 0.0005), suggesting that DNFB inhibition of endogenous creatine kinases completely abolished KCC3-mediated flux of 86 Rb þ (Fig. 6B) . When co-injected with KCC3's RNA, exogenous CK-B did not enhance the 86 Rb þ uptake, but prevented the flux from being fully inhibited at a low concentration of DNFB (50 mM). Instead, an inhibitor concentration of 200 mM (4-fold) was required for significant inhibition of KCC3-mediated flux of 86 Rb þ , when KCC3 and CK-B were co-injected (Fig. 6C) . These data imply that CK-B is required for the activation of KCC3 and suggest a functional interaction between the two proteins.
DISCUSSION
The present study demonstrates that KCC3 physically and functionally interacts with CK-B, an enzyme essential for the generation of ATP. To document the physical interaction between these proteins, we used a variety of approaches, including Y2H system, GST pull-down and immunofluorescence co-localization. Using the Y2H system, we further demonstrated that KCC3's site of binding to CK-B lies within the last 18 amino acids of the transporter, a domain that is lost in all HMSN/ACC-associated truncation mutations. As a result of HMSN/ACC truncation, CK-B's co-localization with KCC3 is no longer observed in immunofluorescence studies. Finally, we used the inhibitory action of DNFB to reveal the crucial role of CK-B activity upon the function of KCC3.
The detection of a physical interaction between KCC3 and CK-B is in agreement with a previous report of a direct interaction between KCC2 and CK-B. However, our observations of a weak in vitro interaction between the two proteins suggest that KCC3 and CK-B may interact mainly in a transient manner. Indeed, we failed to efficiently co-immunoprecipitate the two proteins (data not shown), even though we could observe protein co-localization by double immunofluorescence on fixed KCC3-transfected HeLa cells. To further support this observation of a KCC3/CK-B interaction, we observed that the least deleterious HMSN/ACC-associated truncation mutation abolishes the interaction between the two proteins. Even though CK-B is a cytosolic protein, its association with membrane proteins has been repeatedly demonstrated, its 
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interactors including receptors (thrombin receptor, PAR-1; 18) or channels (ATP-sensitive Kþ channel; 19). Therefore, as a membrane-associated protein, CK-B is considered to be important for producing the ATP required for ion-driving protein activity. These results are consistent with a previous study showing the requirement of creatine kinase for swelling-activated potassium-chloride co-transport in red blood cells (12) . However, the functional significance of the interaction between KCC3 and CK-B remains unclear and the action of ATP on the potassium-chloride co-transporters' function is very complex. Other groups have either demonstrated an ATP-induced activation of KCCs (20, 21) , or have documented that a decrease in ATP levels and the related Mg 2þ depletion effect was linked to KCC's activation, although ATP was required for the full stimulation of the co-transporters (22) , making this a controversial aspect of KCC3's regulation. We show here that CK-B activity is required for the proper functioning of KCC3, which further supports the hypothesis that ATP is necessary for KCC3 activation. Interestingly, the activity of KCC proteins seems to be modulated by phosphorylation involving kinases and phosphatases (23, 24) . CK-B's role could, therefore, be to provide the necessary ATP to specific kinases, which in turn would physically interact with KCC3. Alternatively, CK-B itself could be responsible for the direct phosphorylation of KCC3 (25) .
The swelling-regulation machinery depends on intracellular and extracellular ATP availability (26, 27) . It was shown that ATP removal by apyrase inhibits cell volume restoration under hypotonic stress in several cell types (i.e. astrocytes, hepatocytes, airway and intestinal cells and pancreatic acinar cells) (28 -31) . Hypotonic-swelling stimulates the release of extracellular ATP, which then acts as an autocrinic/paracrinic factor to increase membrane permeability to ions and osmolites (27, 32) . The action of ATP is ultimately to decrease the cell volume (33) . More specifically, it has been reported that in the nervous system an astrocytic ATP release allows a paracrinic signaling to neurons, which are known to have low CK-B, leading to a reduction of the neuronal volume (34, 35) . In addition, the characteristics of necrotic swelling of nerve cells include a deleterious volume increase of the cells associated with a rapid ATP depletion (36) . Given the central role of ATP in nerve cell volume regulation, ATP trafficking is likely to play a key role in controlling cell volume decrease in the nervous system. Solute carriers, along with volume-regulated channels, control the responses involved in cell volume regulation and ion distribution. Among the members of the SLC12 family of proteins, NKCC1 and KCC2 seem to play the most pivotal roles in both neuronal development and functioning (4), but neither one of them is involved in the RVD response in neurons. In contrast, KCC3 is activated under hypotonic conditions to induce the RVD response, which is greatly impaired in HMSN/ACC patients (2, 9) . Volume adaptation to osmotic stress and management of ion distribution are primary or secondary active mechanisms that are highly energy-demanding. In nerve and glial cells, because of their distinctive shape and of the constant intracellular and environmental challenges in ion distribution, energy requirements need to be fine-tuned to an even greater extent. An important amount of energy is also required during nervous system development, given the tasks of elongating and orienting axons, while correct myelin ensheathment occurs. Therefore, an adequate energy supply is of crucial importance for osmotic-dependant integrity of neurons, but is also essential for the proper development of the nervous system. Taking all these observations together, a potential prominent role emerges for the interaction of KCC3 with CK-B, which, when abrogated, could be a major contributor to the neurological defects observed in HMSN/ACC patients. The elucidation and characterization of this protein -protein interaction could, therefore, lead to the better understanding of the pathological mechanisms of HMSN/ACC and ultimately lead to the development of therapies and improved patient management.
MATERIALS AND METHODS
Constructs
The construct containing the full-length KCC3 cDNA in the pGEM vector was kindly provided by Dr David Mount (Harvard Medical School, Boston, MA, USA). To allow the expression of KCC3 protein in mammalian cells, the full-length cDNA in pGEM was digested with SacII and EcoRI and subcloned into the pcDNA 3.1C vector (Invitrogen). Sitedirected mutagenesis was performed using appropriate primers to produce the 3031C!T transition, which is the least deleterious KCC3 truncation characterized so far (R1011X mutant protein). The whole KCC3 CTD was amplified using 5 0 -GGATCCGTCGACTCGATGGTATCCGTGGG CTGGT-3 0 and 5 0 -ATGCGGCCGCTCTAGAGAATTCAGAG TAGGTTAT-3 0 primers, containing BamHI and NotI cloning sites in-frame. The PCR fragment was purified, restriction enzyme-digested with BamHI and NotI and cloned into the corresponding sites in the pGEX 3T-1 vector (Amersham), which allows the production of GST-fused proteins.
For Y2H experiments, CK-B cDNA was purchased from MGC library (IMAGE: 4135106) and Gateway recombination cloning system-compatible primers (5 0 -CACCATGCCCTTC TCCAACAGCCATAATACGCAG-3 0 and 5 0 -CTTCTGGG CCGGCATGAGGTCATCGATTGC-3 0 ) were used to amplify the cDNA. KCC3's whole CTD sequence and distal CTD sequence coding for the last 140 amino acids of KCC3 were amplified using appropriate Gateway recombination cloning system-compatible primers (5 0 -CACCGAGGCACAA TTGGTGAAAG-3 0 and 5 0 -CTTCTGGGCCGGCATGAGGT CATCGATTGC-3 0 respectively). The CK-B and KCC3 PCR products were first cloned into the pENTR entry vector (Invitrogen) and sequence accuracy was confirmed by sequencing. The CK-B fragment was then subcloned into the Gateway-compatible vector pDEST-22 containing a 3 0 -GAL4 activation domain, and KCC3 0 s fragments were subcloned into pDEST-32, which contains 3 0 -GAL4 DNA binding 2708
domain. Subcloning by recombination with LR-recombinase (Invitrogen) was performed according to the manufacturer's instructions.
Yeast two-hybrid
Chemically competent yeast MaV203 cells (MATa; leu2-3,112; trp1-901; his3D200; ade2-101; cyh2R; can1R; gal4D; gal80D; GAL1::lacZ; HIS3UASGAL1::HIS3@LYS2; SPAL10::URA3) were co-transformed with the bait plasmid, which carried the LEU2 marker, and the prey plasmid carrying the TRP1 marker. No self-activation of the bait and the prey strain reporter genes was obtained on synthetic drop-out (SD)-Ura/His medium. Transformed yeast cells were grown on SD -Leu/Trp plates for selection of co-transformed cells. Colonies were picked onto SD -Leu/Trp/His plates for assessment of interactions. Activation of the LacZ reporter was assayed by growing the yeast on filter paper on YPAD plates overnight, lysing the cells in liquid nitrogen and then incubating the filter papers at 378C for 1 h on filters pre-soaked in 100 ml 10% X-gal, 60 ml b-mercaptoethanol and 10 ml Z buffer (100 mM Na 2 HPO 4 , 40 mM NaH 2 PO 4 , 10 mM KCl, 1 mM MgSO 4 , pH 7).
In vitro binding assay
The CTD of KCC3 cloned in pGEX was propagated in the bacterial strain BL21. A single colony was incubated in 3 ml of LB (containing 100 mg/ml ampicillin), grown overnight at 378C and used to produce large-scale cultures. Large-scale cultures were grown until OD 600nm ¼ 0.6-0.8 at 308C and incubated with 0.1 mM IPTG for an additional 30 min to 2 h at 308C. The expression of the fusion protein was assessed by Western blot using a GST-specific antibody. The fusion protein was purified using standard procedures with 500 ml of 50% slurry glutathione-sepharose beads (Amersham). The binding assays were performed for 1 h at 48C in 500 ml of binding solution containing a total brain protein extract, under rocking movement. Following incubation, the beads were rinsed three times for 1 h at 48C in a modified RIPA buffer and carefully drained. The dried beads containing the bound complexes were sent to Wemb Biochem Inc. (Toronto) for protein sequencing using an LC-MS protocol. In parallel, the beads containing the purified complexes were dissociated by boiling for 10 min in sample buffer. The unbound complexes were finally loaded on an SDS-PAGE gel and stained with coomassie blue to assess protein integrity.
Antibodies
Monoclonal anti-GST primary antibody was obtained from Clontech. Monoclonal and polyclonal anti-CK-B primary antibodies were obtained from OEM concept. Polyclonal anti-KCC3 primary antibody, which recognizes the N-terminal domain of the transporter, was obtained from Abnova. Peroxidase-conjugated secondary antibodies for Western blotting were obtained from the Jackson Labs. Secondary antibodies for immunofluorescence were obtained from the Jackson Labs.
HeLa cell transfection and immunocytochemistry
HeLa cells were seeded on sterile plastic coverslips in six-well plates and transfected with 4 mg of full-length KCC3 or R1011X vector DNA using lipofectamine 2000 (Invitrogen), according to the manufacturer's instructions. Following transfection, cells were incubated for 24 h in Dulbecco's modified Eagle's medium (DMEM, GIBCO) containing 10% fetal bovine serum, then washed in PBS and fixed in 4% paraformaldehyde in PBS at room temperature for 10 min. Fixed cells were washed in PBS before being permeabilized in PBS containing 0.2% Triton X-100 (Sigma) at room temperature for 10 min. Permeabilized cells were then washed in PBS, incubated for 1 h in blocking solution (10% NGS in PBS) and transferred to a 5% NGS in PBS solution containing anti-CK-B (OEM concept) and anti-KCC3 (Abnova) antibodies at an appropriate dilution (1:100 and 1:200, respectively). After an overnight incubation, coverslips were washed in PBS and were then incubated for 60 min in 5% NGS in PBS containing fluorescent secondary antibodies. The coverslips were finally washed in PBS and mounted for fluorescent microscopy or confocal visualization.
Mouse brain preparation and immunohistochemistry
Mouse brains fixed in 4% paraformaldehyde were embedded in Tissue-Tek, sectioned parasagitally (10 mm) and placed on glass slides. The sections were processed for immunohistochemistry using a standard in-house protocol (37) . After permeabilization and blocking steps, the sections were incubated overnight in 5% NGS in PBS containing anti-KCC3 and anti-CK-B antibodies (1:150 and 1:200, respectively) and revealed by a 1 h incubation with fluorescent secondary antibodies, followed by slide mounting for confocal microscopy.
Flux assay
In vitro cRNA transcription. The pGEM templates were linearized downstream from the 3 0 -end of the coding sequence with NotI, and the cRNAs were transcribed in vitro using T7 RNA polymerase. Transcript integrity was verified on agarose gels, and concentration was evaluated by absorbance reading at 280 nm and by the densitometric analysis of the corresponding band in ethidium bromide-stained gels.
Xenopus laevis oocyte preparation. Xenopus laevis oocytes were surgically harvested from anesthetized adult female animals and defolliculated at room temperature for 2 h with 2 mg/ml collagenase A. Stage V and VI healthy oocytes were injected with 50 nl of water with or without cRNA (total KCC3 cRNA injected was 10 ng/oocyte and total CK-B cRNA injected was 4.6 ng/oocyte). After injection, oocytes were incubated at 188C for 5 days in Barth's solution (90 mM NaCl, 3 mM KCl, 0.82 mM MgCl 2 , 0.74 mM CaCl 2 , 10 mM HEPES/Tris, 5% (v/v) horse serum, pH 7.6) to allow for recovery and protein expression.
Assessment of KCC3 function. The activity of KCC3 was determined by assessing 86 Rb þ uptake in groups of 20 oocytes or more. The uptake was measured at 328C using a standard protocol: a 60 min incubation period in a hypototonic medium (52 mM Na-Cyclamate, 3.3 mM KCl, 0.74 mM CaCl 2 , 0.82 mM MgCl 2 , 10 mM HEPES/Tris, pH 7.4) with 10 mM ouabain, was followed by incubation in an uptake medium containing 49 mM NaCl, 15 mM Na-Cyclamate, 0.74 mM CaCl 2 , 0.82 mM MgCl 2 , 10 mM HEPES/Tris, pH 7.4, 5 mM 86 Rb þ -Cl 2 and 10 mM ouabain. The KCC3-dependant uptake of 86 
Rb
þ was deduced by exposing groups of cRNAinjected oocytes to 1 mM furosemide. The CKB-dependant uptake was deduced by exposition to 50-200 mM of 2,4-Di-Nitro Fluoro Benzene (DNFB). The uptake experiment was stopped after 45 min by five washes in ice-cold uptake solution without the isotope, to remove extracellular fluid tracer. The oocytes were lysed in 10% sodium dodecyl sulfate and tracer activity was measured for 2 min in a liquid scintillation counter.
Statistical analysis. Statistical significance was defined as P , 0.01, and the results were presented as means + SE. The significance of the differences between oocyte groups was tested by one-way ANOVA and two-tailed Student t-test.
